Medpace
NASDAQ: MEDP
Stock price
614.06 USD
(+0%) TODAY
Financial Performance
5Y price score: 339
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 2,117.6%
US$ Per
Share
By default your notes are visible only to you.
373.0
52-week range
677.9
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
4.1 %
Dividend Yield TTM
-
Market cap $
$ 17,140
Price / Earnings TTM
36
Price / Book TTM
40.1
PEG TTM
1
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
31.5 %
239.9 %
2,117.6 %
Free cash flow per share growth
1.7 %
283 %
1,052.6 %
Earnings per share growth
37.1 %
297.9 %
5,557.1 %
Founded: 1,992
Employees: 5,900
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 23, 2026)
1) Business Environment & Strategy - The business environment in Q2 2026 was strong, with record net bookings and well-managed cancellations. - RFPs increased both sequentially and year-over-year, indicating high-quality opportunities. - Oncology has regained prominence in the company's project mix, contributing over half of the overall bookings. - The company is positioning itself for continued growth into 2027.
2) Financial Results - Q2 2026 revenue was $707.3 million, a 17.2% increase YoY; year-to-date revenue reached $1.41 billion, up 21.7%. - EBITDA for Q2 was $153.4 million, a 17.6% increase YoY, with a margin of 21.7%. - Net income for Q2 was $121.4 million, up 34.5% YoY, translating to $4.25 per diluted share. - Year-to-date net income was $245.2 million, a 19.7% increase YoY.
3) Backlog & Awards - Net new business awards in Q2 increased 28.2% YoY to $795.7 million, with a net book-to-bill ratio of 1.13x. - Ending backlog as of June 30, 2026, was approximately $3 billion, up 4.9% YoY. - Approximately $1.96 billion of backlog is expected to convert to revenue in the next 12 months.
4) Operational Insights & Challenges - Cancellations have improved significantly, contributing to net bookings growth. - The company has implemented initiatives to enhance win rates, which have shown positive results. - There is uncertainty regarding future cancellations, but the overall business environment remains favorable. - The company is managing labor resources effectively with low turnover and expects high single-digit employee growth.
5) Guidance & Outlook - Full-year 2026 revenue is projected between $2.805 billion to $2.885 billion, reflecting growth of 10.9% to 14%. - EBITDA guidance for 2026 is set at $618 million to $642 million, representing growth of 10.8% to 15.1%. - Net income is expected to be in the range of $494 million to $514 million, with diluted earnings per share projected at $17.25 to $17.95.
Bottom line: Medpace is experiencing robust growth driven by a strong business environment and a shift back to oncology projects. With solid financial results and improved backlog dynamics, the outlook for 2026 remains positive, making it an attractive proposition for shareholders.
Annual Reports, Presentations And IR Contacts
Go to the websiteMedpace — Financial Overview, Stock Price, Market Cap
Medpace is a company. Founded in 1992. As of August 26, 2026, the company's market capitalization is $17139458502 with a current stock price of $614.06.